(R)-5'-[3-[4-{1-[1-(3-carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizine-8-yl)-pyrrolidin-3-yl-cyclopropyl]-methylamino}-piperidin-1-yl]-3'-hydroxy]-benzoxazinorifamycin | 1153848-89-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (R)-5'-[3-[4-{1-[1-(3-carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizine-8-yl)-pyrrolidin-3-yl-cyclopropyl]-methylamino}-piperidin-1-yl]-3'-hydroxy]-benzoxazinorifamycin
• CAS: 1153848-89-5
• 化学式: C₇₀H₈₁FN₆O₁₆
• 分子量: 1281.44
• InChiKey: TZPPXPODSWOHFC-UQBXCDFESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.25
• 重原子数：
  93.0
• 可旋转键数：
  9.0
• 环数：
  12.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  292.68
• 氢给体数：
  6.0
• 氢受体数：
  20.0

反应信息

• 作为产物：
  描述：

  3'-hydroxy-benzoxazinorifamycin 、 1-cyclopropyl-7-fluoro-9-methyl-8-{3-[1-(methylpiperidin-4-ylamino)cyclopropyl]pyrrolidin-1-yl}-4-oxo-4H-quinolizine-3-carboxylic acid 在 manganese(IV) oxide 、 三乙胺 作用下， 以 二甲基亚砜 为溶剂， 反应 19.0h， 生成 (R)-5'-[3-[4-{1-[1-(3-carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizine-8-yl)-pyrrolidin-3-yl-cyclopropyl]-methylamino}-piperidin-1-yl]-3'-hydroxy]-benzoxazinorifamycin
  参考文献：
  名称：

  QUINOLONE CARBOXYLIC ACID-SUBSTITUTED RIFAMYCIN DERIVATIVES

  摘要：

  这些化合物包括取代利福霉素衍生物，其中喹诺酸药效基团与苯并噁唑利福霉素或螺环哌嗪利福霉素共价键合。 利福霉素衍生物可用作抗微生物剂，对多种人类和兽医革兰氏阳性和革兰氏阴性病原体有效。 发明化合物的优点在于，利福霉素和喹诺酮抗菌药效基团都与目标感兴趣的病原体具有匹配的药代动力学。同时将多种抗菌药效基团传递到目标病原体，最大程度地实现协同作用并最小化对给药抗生素的耐药性的发展的可能性。

  公开号：

  US20090143373A1

文献信息

• US7884099B2
  申请人：——

  公开号：US7884099B2

  公开（公告）日：2011-02-08
• [EN] QUINOLONE CARBOXYLIC ACID-SUBSTITUTED RIFAMYCIN DERIVATIVES<br/>[FR] DÉRIVÉS DE RIFAMYCINE SUBSTITUÉE PAR L'ACIDE QUINOLONE-CARBOXYLIQUE
  申请人：CUMBRE PHARMACEUTICALS INC

  公开号：WO2009064792A1

  公开（公告）日：2009-05-22

  The compounds include substituted rifamycin derivatives in which a quinolone carboxylic acid pharmacophore is covalently bonded to a benzoxazinorifamycin or a spiropiperidinorifamycin. The rifamycin derivatives are useful as antimicrobial agents and are effective against a number of human and veterinary Gram positive and Gram negative pathogens. The advantage of the inventive compounds is that both the rifamycin and quinolone antibacterial pharmacophores are co-delivered with matched pharmacokinetics to the targeted pathogens of interests. Delivery of multiple antibacterial pharmacophores simultaneously to the targeted pathogens has the maximum chance of achieving synergy and minimizing the development of resistance to the antibiotics given.